Converge Bio, an AI drug discovery startup, has successfully raised $25 million in a Series A funding round led by Bessemer Venture Partners, with support from executives at Meta, OpenAI, and Wiz. This investment highlights growing interest and confidence in AI-driven solutions for the pharmaceutical industry.